Clinical Trials on FGFR1 Gene Amplification
Total 0 results
Nothing found
Sponsors and Collaborators
- ASSOCIATION POUR LE DEVELOPPEMENT EN FECONDATION IN VITRO
- Ouctomes Research Consortium, Cleveland Clinic, Ohio, USA
- Sahachat Aueyingsak
- ECMC
- Åke Wibergs Stiftelse
- Bassam Abdulkarim
- The Australia-Israel Scientific Exchange Foundation (AISEF)
- National Institute of Cardiovascular Diseases, Bangladesh
- Dr Philippe METELLUS
- Glasgow Western Infirmary
- the people hospital of Linzhi
- IRCCS Istituto Auxologico Italiano, Milano, Italy
- Etan Orgel
- Direction Interarmées du Service de Santé des Armées (DIASS) de Cayenne, French Guiana
- Centro Universitário Franciscano
- Hospitales Universitarios Virgen del Rocío
- Daniela Pacella - University of Naples Federico II, Naples
- ADOR - Territorial Support Network, Device and Tools for Primary Care Teams
- AlpinARC
- Sublimity Therapeutics Holdco Limited
- View Full List
Medical Conditions
- Degenerative Spondylolisthesis G1
- Orthopaedic Disorders
- Panniculectomy
- Value-Based Health Insurance
- Genetic Risk Factor
- Very Long Chain Acyl Coa Dehydrogenase Deficiency
- Patients With Leptomeningeal Disease
- Hyperprolinemia
- Failed Open Reduction Internal Fixation (ORIF) of a Radial Head Fracture
- Implanted With Any Currently (and Any Future) FDA-approved Medtronic ICD or CRT Device
- Adult Patients Undergoing Surgery That Requires General Anesthesia
- Legal History
- Interviews
- Bladder Cancer TNM Staging Primary Tumor (T) T2B
- Pancreaticoduodenectomy
- Initiation of Depo-Provera (DMPA)
- Eosinophil Blood Count
- Ability to Swim 100m Independent Freestyle
- Progression to PD-1 Antibody
- Transitional Cell Carcinoma of Renal Pelvis
- View Full List
Drug Interventions
- Metoclopramide + dexamethasone
- HBM4003 and Triprilimab
- Epirubicin hydrochloride
- Erythropoietin
- 5-Fluoro-uracil
- Paliperidone palmitate
- Prasugrel
- Mepivacaine
- ASP8062
- Nimotuzumab
- Antibiotic treatment
- 6% hetastarch
- Omeprazole 20mg
- Injectable Insulin
- Gefitinib
- ATG-008 30 mg, orally, QD, each 4 week (28-day) a cycle
- 0% N2O
- IV rtPA (intravenous recombinant plasminogen activator)
- Cefuroxime 750mg oral
- UFUR and Iressa
- View Full List
CROs by country
- Contract Research Organizations in Albania
- Contract Research Organizations in Burundi
- Contract Research Organizations in Dominican Republic
- Contract Research Organizations in Equatorial Guinea
- Contract Research Organizations in Germany
- Contract Research Organizations in Greece
- Contract Research Organizations in Ireland
- Contract Research Organizations in Malaysia
- Contract Research Organizations in Pakistan
- Contract Research Organizations in Philippines
- Contract Research Organizations in Saudi Arabia
- Contract Research Organizations in Trinidad & Tobago
- Contract Research Organizations in Uganda
- CRO list by country